Addex Therapeutics Ltd
ADXN
$9.00
$0.19172.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 174.52% | 164.32% | 146.34% | 133.19% | 30.00% |
| Total Depreciation and Amortization | 1,521.80% | 1,554.20% | 118.21% | -18.66% | -94.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -584.20% | -580.07% | -550.33% | -532.41% | -18.38% |
| Change in Net Operating Assets | -241.95% | -577.64% | 98.54% | 69.96% | 358.47% |
| Cash from Operations | 52.41% | 31.84% | 40.81% | 23.99% | 39.40% |
| Capital Expenditure | 70.00% | 80.52% | 53.97% | 63.93% | -51.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 139,383.78% | -- |
| Cash from Investing | 102,820.00% | 66,801.30% | 81,888.89% | 215,045.83% | -1,350.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 96.25% | 73.85% | 49.59% | 24.05% | 28.29% |
| Issuance of Common Stock | -99.68% | -89.76% | -89.09% | -93.71% | -50.97% |
| Repurchase of Common Stock | 51.15% | 48.70% | 61.44% | 60.95% | 68.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.04% | -101.13% | -101.20% | -102.27% | 32.85% |
| Cash from Financing | -99.12% | -97.90% | -98.98% | -101.51% | -3.84% |
| Foreign Exchange rate Adjustments | 93.75% | 128.41% | 60.60% | 71.94% | -12.92% |
| Miscellaneous Cash Flow Adjustments | 196.68% | -- | -- | -- | -- |
| Net Change in Cash | 128.57% | 80.16% | 72.24% | -136.13% | 53.17% |